There is a paucity of information on the utilization patterns of liver transplantation (LT) for HIV-positive individuals. The aim of this study is to examine the trends in LT of HIV patients in the ...US. This study was a retrospective analysis using the UNOS database (1999–2008). There were 135 HIV-positive patients. There was a steady increase in the number of LT recipients over time as well as regional variation. Ethnic minorities accounted for 33.3% and there was no ethnic difference in survival. Though LT for HIV-positive patients is on the rise, significant variations exist in patient demographics, geographic location, and insurance payer.
Studies to address the ethnic minorities in liver transplantation (LT) have focused traditionally on African Americans and Hispanics. Although, the Asian population accounts for 4.4% of the US ...population, there is limited information on transplantation trends for this ethnic group. The aim of this study was to evaluate the transplantation trends and determine survival patterns of Asian LT recipients.
The United Network for Organ Sharing database was reviewed for all Asian adult (>18 years) recipients who underwent LT between 1998 and 2007 (n=1953). The data collected included demographics, diagnosis, survival data, and United Network for Organ Sharing regions.
During the study period 1953 Asians received liver transplantation. The most frequent indication for transplantation among Asians was HBV (28.1%) in contrast to the non-Asian group in which HCV (29.6%) was the most common. The 5-yr Patient and graft survival was 76%, 74%, 73%, 65% and 71%, 68%, 67% and 57% for Asian, Hispanic, White and Black respectively.
We found (1) regional variation and differences in liver disease pattern among Asian population; and (2) overall LT recipients of Asian ethnicity have a significant survival advantage in comparison to non-Asian groups.
Hepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ...ribavirin (RBV) in 2 phase 3, open-label, multicenter studies in patients with stage 4 or 5 chronic kidney disease (CKD).
RUBY-I, Cohort 2 enrolled treatment-naïve or -experienced patients with HCV genotype (GT) 1a or 1b infection, with or without cirrhosis. Patients received 12 weeks (24 weeks for GT1a patients with cirrhosis) of OBV/PTV/r + DSV; all GT1a patients received RBV. RUBY-II enrolled treatment-naïve patients with GT1a or GT4 infection without cirrhosis. All patients received 12 weeks of RBV-free treatment: OBV/PTV/r + DSV for GT1a-infected patients; OBV/PTV/r for GT4-infected patients. The primary endpoint was sustained virologic response at posttreatment week 12 (SVR12).
RUBY-I, Cohort 2 and RUBY-II enrolled 66 patients, including 50 (76%) on dialysis; 15 (23%) had compensated cirrhosis. Overall, the SVR12 rate was 95% (63/66); 1 patient had virologic failure. There were 3 discontinuations due to adverse events. Seventy-three percent (27/37) of patients receiving RBV had adverse events leading to RBV dose modification. The RBV-free RUBY-II study had no hemoglobin-associated adverse events.
Treatment with OBV/PTV/r ± DSV ± RBV was well tolerated and patients with HCV GT1 or 4 infection and stage 4 or 5 CKD had high SVR12 rates, including patients with compensated cirrhosis and/or prior treatment experience.
Seroepidemiology of hepatitis A virus in Kuwait Alkhalidi, Jameela; Alenezi, Bader; Al-Mufti, Seham ...
World journal of gastroenterology : WJG,
01/2009, Letnik:
15, Številka:
1
Journal Article
Odprti dostop
AIM： To find the current seroepidemiology of hepatitis A virus （HAV） in Kuwait. METHODS： A total of 2851 Kuwaitis applying for new jobs were screened.RESULTS： HAV-positive cases were 28.8%; 59% were ...males and 41% were females. The highest prevalence was in the Ahmadi area. High prevalence was among the group of non-educated rather than educated parents. This is the first study in Kuwait demonstrating the shifting epidemiology of HAV. CONCLUSION： This study reflects the need of the Kuwaiti population for an HAV vaccine.
End-stage liver disease is a major cause of morbidity and mortality among ethnic minorities. In the United States, ethnic minorities comprise approximately 30% of all adult liver transplantations ...performed annually. Several studies have suggested that ethnic populations differ with respect to access and outcomes in the pre- and post-transplantation setting. This paper will review the existing literature on ethnic variations in the adult liver transplantation population.
PDF
